Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects
- Conditions
- Heathy Volunteer
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT03363815
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
Pharmacokinetics of Metformin Intolerance
- Conditions
- Diabetes Mellitus, Type 2Metformin Adverse Reaction
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- NHS Tayside
- Target Recruit Count
- 20
- Registration Number
- NCT03361878
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Biphasic insulin aspart 30Drug: INSULIN GLARGINE (HOE901)Drug: MetforminDrug: Insulin GlulisineDrug: RepaglinideDrug: Acarbose
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 384
- Registration Number
- NCT03359837
- Locations
- 🇨🇳
CHINA, China, China
Metformin Treatment for Colon Cancer
- Conditions
- Colon Cancer
- Interventions
- Drug: Placebo oral capsuleDrug: Metformin Hydrochloride
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT03359681
- Locations
- 🇩🇰
Department of Surgery, Slagelse Hospital, Slagelse, Denmark
Research of Exenatide for Overweight/Obese PCOS Patients With IGR
- Conditions
- Overweight and ObesityDisorder of Glucose RegulationPolycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 183
- Registration Number
- NCT03352869
- Locations
- 🇨🇳
Renji Hospital Department of Endocrinology and Metabolism, Shanghai, China
Cardiometabolic Disease and Pulmonary Hypertension
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT03349775
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 287
- Registration Number
- NCT03349684
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Sun Yat-Sen Memorial Hosp. Sun Yat-Sen Univ., Guangzhou, Guangdong, China
Metformin in Heart Failure Without Diabetes
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 6
- Registration Number
- NCT03331861
- Locations
- 🇺🇸
New York Hospital - Columbia University Irving Medical Center, New York, New York, United States
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 954
- Registration Number
- NCT03332771
- Locations
- 🇺🇸
Investigational Site Number 8407074, Bradenton, Florida, United States
🇺🇸Investigational Site Number 8407111, Dallas, Texas, United States
🇺🇸Investigational Site Number 8407078, Carmichael, California, United States
Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus
- Conditions
- Gestational Diabetes Mellitus in Pregnancy
- Interventions
- Drug: InsulinDrug: Metformin
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Services Institute of Medical Sciences, Pakistan
- Target Recruit Count
- 278
- Registration Number
- NCT03320694
- Locations
- 🇵🇰
Services Institute of Medical Sciences, Lahore, Punjab, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.